The FDA’s approval of Biogen’s Alzheimer’s drug Aduhelm in June was heralded as a historic triumph.

The FDA’s approval of Biogen’s Alzheimer’s drug Aduhelm in June was heralded as a historic triumph. But the excitement around the drug has receded. Why is Biogen’s drug so controversial? Watch the full video here: https://t.co/gM0AITZpu3 pic.twitter.com/52ho9YxyLM

— CNBC (@CNBC) May 1, 2022